Itemoids

New York

The Atlantic Announces Hillary Rodham Clinton and New Speakers for the 15th Annual Atlantic Festival

The Atlantic

www.theatlantic.com › press-releases › archive › 2023 › 09 › atlantic-festival-announces-hillary-rodham-clinton › 675247

This story seems to be about:

The Atlantic is today announcing new speakers––including former Secretary of State and United States Senator Hillary Rodham Clinton––appearing at the 15th annual Atlantic Festival, taking place on Thursday, September 28, and Friday, September 29, at The Wharf in Washington, D.C. Clinton will be in conversation with The Atlantic’s editor in chief, Jeffrey Goldberg, discussing existential threats to democracy. Goldberg will also interview Secretary of State Antony Blinken and former House Speaker Nancy Pelosi. Also announced today are an interview with Secretary of the Department of Health and Human Services Xavier Becerra with senior editor Vann R. Newkirk II; and a conversation led by Laurene Powell Jobs, the founder and president of Emerson Collective, with the secretary of the Smithsonian Institution, Lonnie G. Bunch III.

The Atlantic is pleased to welcome and announce CBS News as the exclusive broadcast media partner for The Atlantic Festival. CBS News journalists will moderate a number of conversations at the festival, and the network will have a presence throughout the event.

The festival’s two days will feature interviews with the actor, producer, and activist Kerry Washington; Governor Josh Shapiro of Pennsylvania; Governor Spencer Cox of Utah; Representative Joaquin Castro; the 2024 Republican presidential candidate Will Hurd; former Representative Gabby Giffords; the chief technology officer of OpenAI, Mira Murati; and the authors Chimamanda Ngozi Adichie, Lauren Groff, and Jake Tapper. The evening of September 28 will feature the debut of Netflix’s forthcoming docuseries Big Vape: The Rise and Fall of Juul, followed by a conversation featuring the series’s director and renowned documentarian, R. J. Cutler. September 29 will feature a night of live storytelling with the filmmaker Spike Lee, in conversation with the Atlantic contributing writer Jemele Hill.

Additional program announcements include:

Along with Goldberg, Newkirk, and Hill, many of The Atlantic’s journalists will lead and participate in conversation across the festival, including Tim Alberta, Ross Andersen, Julie Beck, Gal Beckerman, Ron Brownstein, McKay Coppins, Caitlin Dickerson, David Frum, Claudine Ebeid, Franklin Foer, Megan Garber, Adam Harris, Sarah Laskow, Helen Lewis, Shirley Li, Mark Leibovich, Annie Lowrey, Tom Nichols, Elaina Plott Calabro, Rebecca Rosen, Hanna Rosin, Clint Smith, Andrea Valdez, and many more.

CBS News’ anchors and correspondents who will moderate festival events are John Dickerson, anchor of CBS News Prime Time with John Dickerson; Nancy Cordes, chief White House correspondent; Weijia Jiang, senior White House correspondent; and correspondent Christina Ruffini.

The Big Story: The Future of Major League Baseball (September 28, 4:30–5:30 p.m.)
The Atlantic staff writer Mark Leibovich will be in conversation with Major League Baseball executives Morgan Sword and Raúl Ibañez for a discussion on the league’s recent innovations and the future of America’s pastime.

Radio Atlantic LIVE (September 29, 5:30–6:30 p.m.)
The host of Radio Atlantic, Hanna Rosin, will lead a live podcast taping with the Atlantic staff writers Elaina Plott Calabro and Franklin Foer to talk about their in-depth reporting on the Biden administration and look ahead to the 2024 presidential election.

The Climate Summit (September 28, 2:30–4 p.m.)
This session will address today’s most urgent climate challenges and offer solutions for a more resilient future. Summit participants include David M. Turk, deputy secretary of the U.S. Department of Energy; and Rohit Aggarwala, commissioner of the Department of Environmental Protection, and chief climate officer of New York City.

The Small-Business Summit: Scaling Sustainability (September 29, 12:45–2:15 p.m.)
The Atlantic staff writer Annie Lowrey will moderate this newly announced summit with speakers including Omi Shelly Bell, the founder and CEO of Black Girl Ventures; Emi Reyes, the CEO of the Latino Economic Development Center; Amir Tarighat, a co-founder and the CEO of Agency; Celena Gill, a co-founder and the CEO of Frères Branchiaux; and Ramunda Lark Young, a co-founder and owner of MahoganyBooks.

In Pursuit of Happiness Forum (September 29, 1–3 p.m.)
Cleo Wade and freestyle+ (part of Freestyle Love Supreme) have both been added to the In Pursuit of Happiness forum, which is led by the Atlantic contributing writer Arthur C. Brooks, and which also features the author Cheryl Strayed.

Atlantic Watch: Bad Press (September 29, 2:45–5:30 p.m.)
A screening of the new documentary Bad Press. Out of 574 federally recognized tribes, the Muscogee Nation was one of only five to establish a free and independent press—until the tribe’s legislative branch abruptly repealed the landmark Free Press Act in advance of an election, prompting a rogue reporter to take matters into her own hands. The screening will be followed by a conversation with the co-directors Rebecca Landsberry-Baker and Joe Peeler, and Angel Ellis, the journalist at the center of the story.

In a session produced by our underwriter, supermodel, entrepreneur, and philanthropist Karlie Kloss and Mustafa Suleyman, a co-founder and the CEO of Inflection AI, will be interviewed by The Atlantic’s CEO, Nicholas Thompson, during “Leaps by Bayer Presents: Mind to Machine.” (September 28, 12:15–1 p.m.)

The 2023 Atlantic Festival is made possible through the generous support of Presenting Level Underwriters Leaps by Bayer, Pfizer, and Southern Company; Supporting Level Underwriter Allstate; and Contributing Level Underwriters AHIP, Barbour, Boston Consulting Group, City of Hope, Eli Lilly and Company, Genentech, Goldman Sachs, the John D. and Catherine T. MacArthur Foundation, and Visit Seattle.

The Atlantic Festival
September 28–29, 2023
The Wharf, D.C., and Virtually
For Passes: https://theatlanticfestival.com

America Is Telling Itself a Lie About Roadkill

The Atlantic

www.theatlantic.com › science › archive › 2023 › 09 › roadkill-endangered-animals-amphibians › 675241

The great irony of roadkill is this: Its most conspicuous victims tend to be those least in need of saving. Simple probability dictates that you’re more likely to collide with a common animal—​a squirrel, a raccoon, a white-​tailed deer—​than a scarce one. The roadside dead tend to be culled from the ranks of the urban, the resilient, the ubiquitous.

But roadkill is also a culprit in our planet’s current mass die-​off. Every year American cars hit more than 1 million large animals, such as deer, elk, and moose, and as many as 340 million birds; across the continent, roadkill may claim the lives of billions of pollinating insects. The ranks of the victims include many endangered species: One 2008 congressional report found that traffic existentially threatens at least 21 critters in the U.S., including the Houston toad and the Hawaiian goose. If the last-ever California tiger salamander shuffles off this mortal coil, the odds are decent that it will happen on rain-​slick blacktop one damp spring night.

The poster groups for roadkill’s hidden toll are reptiles and amphibians, known collectively as “herps.” The small bodies and secretive habits of herps conceal their dominance: Many forests in the eastern United States support more salamanders than small mammals and birds combined. But about one in five reptile species and two in five amphibian species are threatened with extinction, and many more are on their way. Snapping turtles and spotted salamanders aren’t on the verge of vanishing altogether, but they’ve become rarer and more isolated, retreating from our landscapes and our lives. Biologists refer to localized extinctions—​a pond emptied of frogs here, a pool robbed of salamanders there—​as extirpations, many small losses that over time can amount to a very big one. The wetlands advocate David M. Carroll has lamented “the silence of the frogs,” a hush as disquieting as the one that terrified Rachel Carson.

The forces muzzling the frogs and other herps are many—​habitat loss, fungal disease, pollution—​but it’s not a coincidence that herps are predisposed to become roadkill. Reptiles and amphibians move slowly and, as cold-​blooded creatures, they gravitate toward warm surfaces, whether limestone or asphalt. Turtles lumber across lakefront streets to deposit their eggs; snakes slither over highways to huddle in hibernacula. Worst of all, some herps, such as northern leopard frogs, don’t attempt to race between cars, as deer do, or avoid roads altogether, as grizzly bears do. Instead, they’re what scientists call “nonresponders”: animals who are unfazed by traffic, even when prudence would serve them well.  

Amphibians, whose name means “double life,” are especially susceptible. Frogs, toads, and salamanders belong to two worlds: the water in which they’re born and the upland forests where many species, upon swapping gills for lungs, spend their adulthood. When you have a toe in two realms, you must migrate between them. Amphibians move most frenziedly on spring nights, when rain refills the ephemeral pools that dimple forest floors and summons them to mate. Wood frogs that spent the winter as cold and hard as Popsicles, preserved by their own natural antifreeze, thaw and stir. Salamanders clamber from their catacombs. Peepers trill with a vehemence out of all proportion to their thumbnail-​size bodies. Thousands of minuscule lives go on the march, called by wetlands that will soon be cloudy with gelatinous egg masses. In some places the emergence occurs over weeks; in others, in a few bacchanals known as Big Nights. And a salamander on a Big Night will cross any road in her path—​come hell, high water, or Honda.

When an aggregation of libidinous herps boils over a road, the outcome is what some biologists call, none too scientifically, a “massive squishing.” Squishing statistics are both appalling and abstract, in the way that astronomical death tolls often are: nearly 28,000 leopard frogs killed over two separate two-year periods on a Lake Erie causeway; up to 10,000 red-​sided garter snakes slain in one season in Manitoba; 2,500 toads flattened on a French road. In Indiana, scientists who counted more than 10,000 crushed animals found that 95 percent were reptiles and amphibians. You’ve probably never heard one pop beneath your tires, but in many places herps—​not deer, not squirrels—​make up most vertebrate roadkill.

One of roadkill’s cruelest aspects is not how many animals it culls: it’s which ones. Wild ecosystems weed out the sick and the old—​the diseased fawn devoured by wolves, the senescent moose who collapses in a snowdrift. Roadkill, by contrast, is an equal-​opportunity predator, as apt to eliminate the strong as the feeble. In Canada, for instance, vehicle-​killed elk are healthier than animals slain by wolves and cougars. The same dynamic plagues amphibians. In New York, researchers discovered that roadside ponds held unusually small salamander-egg masses, likely because young females were getting crushed before they could grow into big, ripe breeders. Cars not only kill animals, in other words: They crush the very individuals who would otherwise help populations recover. Even a few deaths can add up. In Ontario, researchers have found, just nine roadkills a year couuld be enough to eventually rub out a cluster of black rat snakes; in central and western Massachusetts, a roadkill rate above 10 percent may eliminate any given group of spotted salamanders. By that standard, up to three-​quarters of the region’s populations might be doomed.

For a long time, however, few considered roadkill a threat. Cars might have been pulverizing millions of frogs each year, but millions more crawled in the wings. Even Henry David Thoreau considered wagon-​flattenings cause for perverse celebration. “I love to see that Nature is so rife with life that myriads can be afforded to be sacrificed … that tender organizations can be so serenely squashed out of existence like pulp,” Thoreau raved in Walden, “tadpoles which herons gobble up, and tortoises and toads run over in the road.”

Many biologists concurred. Roadkill was widely considered “compensatory mortality,” a form of death balanced by the scales of life. If more frogs were flattened, the thinking went, maybe fewer would get eaten by predators, or there would be more food for their tadpoles. “When you deal with a group like amphibians, which have a high reproductive rate, people just think, Well, they’ll be able to compensate for road mortality,” a Canadian biologist named Lenore Fahrig told me. “The idea that roads actually have effects on populations, I don’t think that was on anybody’s radar at all.”

Fahrig put the lie to that attitude. In the 1990s, she noticed that the herp carnage was worse on a quieter road near her Ottawa home than on the busier one—even though frogs readily cross busy streets, fewer cars had somehow produced more death. Fahrig puzzled over the conundrum and came up with a hypothesis: The busy road didn’t have many frogkills, because there weren’t many frogs left to kill. Traffic, she suspected, had already wiped out the local population. Curiosity piqued, Fahrig devised a study to test her hunch. In the spring of 1993, she and colleagues drove around Ottawa, scanning roadsides for dead frogs and toads, and stopping to listen for the trills, croaks, and squeaks of live ones. Sure enough, the busiest roads had the poorest remnant amphibian communities. Given enough time and traffic, roadkill could indeed diminish a population, even extirpate it. Roadkill was not exclusively a source of compensatory mortality: It could also be additive mortality, death that never came out in nature’s wash.

In a vacuum, reptiles and amphibians might be able to endure all of this. But they’re also bedeviled by “synergistic” threats, dangers that compound in pernicious ways. The same suburbanization that drains marshes also funnels more traffic through wetlands, piling roadkill atop habitat loss. As populations bow beneath comorbidities, they become more vulnerable. Healthy animal communities ride natural fluctuations like gulls bobbing in the surf, buffered from extinction by sheer abundance. Plunge too deep into the wave’s trough, though, and a few mishaps—​a dozen SUVs on a soggy night, say—​can be fatal. And landscapes, once drained of their herps, rarely refill. The roads that run between wetlands and uplands also sever the link between these realms, destroying any frog or newt brazen enough to strike out toward an empty pond. Roads disunite land and water, short-​circuiting the experience of amphibiousness.

The diminishment of herps is a hard problem to grasp. Utter extinction, the fate that befell the passenger pigeon and the Carolina parakeet, is a concept universally understood. Yet extinction is rarely instantaneous, and the gradual ebbing of abundance that precedes it strains language. Some researchers have called such insidious losses “defaunation”; others know them as “biological annihilation.” The biologist E. O. Wilson favored “Eremocene”: the age of loneliness, a near and desolate future in which humankind bestrides an empty world, or perhaps drives over it.

This article has been adapted from Ben Goldfarb’s forthcoming book, Crossings: How Road Ecology Is Shaping the Future of Our Planet.

We Have No Drugs to Treat the Deadliest Eating Disorder

The Atlantic

www.theatlantic.com › health › archive › 2023 › 09 › anorexia-drug-resistance-eating-disorder › 675246

In the 1970s, they tried lithium. Then it was zinc and THC. Anti-anxiety drugs had their turn. So did Prozac and SSRIs and atypical antidepressants. Nothing worked. Patients with anorexia were still unable to bring themselves to eat, still stuck in rigid thought patterns, still chillingly underweight.

A few years ago, a group led by Evelyn Attia, the director of the Center for Eating Disorders at New York Presbyterian Hospital and the New York State Psychiatric Institute, tried giving patients an antipsychotic drug called olanzapine, normally used to treat schizophrenia and bipolar disorder, and known to cause weight gain as a side effect. Those patients in her study who were on olanzapine increased their BMI a bit more than others who were taking a placebo, but the two groups showed no difference in their cognitive and psychological symptoms. This was the only medication trial for treating anorexia that has shown any positive effect at all, Attia told me, and even then, the effects were “very modest.”

Despite nearly half a century of attempts, no pill or shot has been identified to effectively treat anorexia nervosa. Anorexia is well known to be the deadliest eating disorder; the only psychiatric diagnosis with a higher death rate is opioid-use disorder. A 2020 review found people who have been hospitalized for the disease are more than five times likelier to die than their peers without it. The National Institutes of Health has devoted more than $100 million over the past decade to studying anorexia, yet researchers have not found a single compound that reliably helps people with the disorder.

Other eating disorders aren’t nearly so resistant to treatment. The FDA has approved fluoxetine (a.k.a. Prozac) to treat bulimia nervosa and binge-eating disorder (BED); doctors prescribe additional SSRIs off-label to treat both conditions, with a fair rate of success. An ADHD drug, Vyvanse, was approved for BED within two years of the disorder’s official recognition. But when it comes to anorexia, “we’ve tried, I don’t know, eight or 10 fundamentally different kinds of approaches without much in the way of success,” says Scott Crow, an adjunct psychology professor at the University of Minnesota and the vice president of psychiatry for Accanto Health.

The discrepancy is puzzling to anorexia specialists and researchers. “We don’t fully understand why medications work so differently in this group, and boy, do they ever work differently,” Attia told me. Still, experts have some ideas. Over the past few decades, they have been learning about the changes in brain activity that accompany anorexia. For example, Walter Kaye, the founder and executive director of the Eating Disorders Program at UC San Diego, told me that the neurotransmitters serotonin and dopamine, both of which are involved in the brain’s reward system, seem to act differently in anorexia patients.

Perhaps some underlying differences in brain chemistry and function play a role in anorexia patients’ extreme aversion to eating. Or perhaps, the experts I spoke with suggested, these brain changes are at least in part a result of patients’ malnourishment. People with anorexia suffer from many effects of malnutrition: Their bones are more brittle; their brain is smaller; their heart beats slower; their breath comes shorter; their wounds fail to heal. Maybe their neurons respond differently to psychoactive drugs too.

[Read: The challenge of treating anorexia in adults]

Psychiatrists have found that many patients with anorexia don’t improve with treatment even when medicines are prescribed for conditions other than their eating disorder. If an anorexia patient also has anxiety, for example, taking an anti-anxiety drug would likely fail to relieve either set of symptoms, Attia told me. “Time and again, investigators have found very little or no difference between active medication and placebo in randomized controlled trials,” she said. The fact that fluoxetine seems to help anorexia patients avoid relapse—but only when it’s given after they’ve regained a healthy weight—also supports the notion that malnourished brains don’t respond so well to psychoactive medication. (In that case, the effect might be especially acute for people with anorexia nervosa, because they tend to have lower BMIs than people with other eating disorders.)

Why exactly this would be true remains a mystery. Attia noted that proteins and certain fats have been shown to be crucial for brain function; get too little of either, and the brain might not metabolize drugs in expected ways. Both she and Kaye suggested a possible role for tryptophan, an amino acid that humans get only from food. Tryptophan is converted into serotonin (among other things) when we release insulin after a meal, Kaye said, but in anorexia patients, whose insulin levels tend to be low, that process could end up off-kilter. “We suspect that that might be the reason why [SSRIs] don’t work very well,” he said, though he emphasized that the theory is very speculative.

In the absence of meaningful pharmacologic intervention, doctors who treat anorexia rely on methods such as nutrition counseling and psychotherapy. But even non-pharmaceutical interventions, such as cognitive behavioral therapy, are more effective at treating bulimia and binge-eating disorder than anorexia. Studies from around the world have shown that as many as half of people with anorexia relapse.

Colleen Clarkin Schreyer, a clinical psychologist at Johns Hopkins University, sees both patients with anorexia nervosa and those with bulimia nervosa, and told me that the former can be more difficult to treat—“but not just because of the fact that we don’t have any medication to help us along. I often find that patients with anorexia nervosa are more ambivalent about making behavior change.” Bulimia patients, she said, tend to feel shame about their condition, because binge eating is stigmatized and, well, no one likes vomit. But anorexia patients might be praised for skipping meals or rapidly losing weight, despite the fact that their behaviors can be just as dangerous over the long term as binging and vomiting.

[Read: Raising a daughter with a body like mine]

Researchers are still trying to find substances that can help anorexia patients. Crow told me that case studies testing a synthetic version of leptin, a naturally occurring human hormone, have produced interesting data. Meanwhile, some early research into using psychedelics, including ketamine, psilocybin, and ayahuasca, suggests that they may relieve some symptoms in some cases. But until randomized, controlled trials are conducted, we won’t know whether or how well any psychedelic really works. Kaye is currently recruiting participants for such a study of psilocybin, which is planned to have multiple sites in the U.S. and Europe.

Pharmaceutical companies just don’t seem that enthusiastic about testing treatments for anorexia, Crow said. “I think that drug makers have taken to heart the message that the mortality is high” among anorexia patients, he told me, and thus avoid the risk of having deaths occur during their clinical trials. And drug development isn’t the only area where the study of anorexia has fallen short. Research on eating disorders tends to be underfunded on the whole, Crow said. That stems, in part, from “a widely prevailing belief that this is something that people could or should just stop … I wish that were how it works, frankly. But it’s not.”